Theranexus (EPA:ALTHX) | WebDisclosure

BRIEF

published on 07/03/2024 at 07:35, 4 months 20 days ago

Theranexus, CRNL et CERMEP lauréats du projet "Pacte de recherche 2024" d'Auvergne-Rhône-Alpes

Recherche Auvergne-Rhône-Alpes Theranexus Neurologie Neuroimagerie
BRIEF

published on 07/03/2024 at 07:35, 4 months 20 days ago

Theranexus, CRNL and CERMEP winners of the Auvergne-Rhône-Alpes “Research Pact 2024” project

Research Neurology Auvergne-Rhône-Alpes Theranexus Neuroimaging
PRESS RELEASE

published on 07/03/2024 at 07:30, 4 months 20 days ago

THERANEXUS, LYON NEUROSCIENCE RESEARCH CENTER AND CERMEP WIN THE "2024 RESEARCH PACT" PROJECT FOR THE AUVERGNE-RHÔNE-ALPES REGION
Theranexus, Lyon Neuroscience Research Center, and CERMEP win research pact project 'IMASO' in Auvergne-Rhône-Alpes Region for preclinical neuroimaging in rare neurological diseases

Theranexus Neurological Diseases Research Pact Auvergne-Rhône-Alpes Region Preclinical Neuroimaging
PRESS RELEASE

published on 07/03/2024 at 07:30, 4 months 20 days ago

THERANEXUS, LE CENTRE DE RECHERCHE EN NEUROSCIENCES DE LYON ET LE CERMEP, LAURÉATS DU PROJET " PACTE DE RECHERCHE 2024 " DE LA REGION AUVERGNE-RHÔNE-ALPES
Theranexus, CRNL, and CERMEP win 'Pacte de recherche 2024' project in Auvergne-Rhône-Alpes to develop new neuroimaging tools for rare neurological diseases treatment

Theranexus Rare Neurological Diseases Neuroimaging CRNL CERMEP
BRIEF

published on 06/06/2024 at 07:35, 5 months 17 days ago

Theranexus et BBDF annoncent des résultats positifs à 18 mois pour Batten-1 dans une étude de phase 1/2

Theranexus Batten-1 Maladie De Batten BBDF Neurofilaments
BRIEF

published on 06/06/2024 at 07:35, 5 months 17 days ago

Theranexus and BBDF Announce Positive Results at 18 Months for Batten-1 in Phase 1/2 Study

Theranexus Batten-1 BBDF Batten Disease Neurofilaments
PRESS RELEASE

published on 06/06/2024 at 07:30, 5 months 17 days ago

Theranexus and BBDF confirm positive 18-month results for Batten-1 in Phase I/II trial based on neurofilaments, a biomarker of neuronal death
Theranexus and BBDF confirm positive results in Phase I/II trial evaluating Batten-1 drug for CLN3 Batten disease after 18 months of treatment, showing decline in NfL biomarker levels and therapeutic potential

Theranexus Batten-1 BBDF CLN3 Batten Disease Neurofilament Light Chains
PRESS RELEASE

published on 06/06/2024 at 07:30, 5 months 17 days ago

Theranexus et BBDF confirment les résultats positifs à 18 mois de Batten-1 dans l'étude de phase 1/2 sur les neurofilaments, un biomarqueur de la mort neuronale
Theranexus et BBDF confirment les résultats positifs à 18 mois de l'étude de phase 1/2 sur les neurofilaments, biomarqueur de la mort neuronale, concernant le médicament Batten-1 dans la maladie de Batten (CLN3)

Theranexus Batten-1 Maladie De Batten BBDF Neurofilaments
BRIEF

published on 05/02/2024 at 07:35, 6 months 21 days ago

Theranexus unveils its universal registration document for 2023

2023 Biopharmaceutical Universal Registration Document Theranexus Rare Neurological Diseases
BRIEF

published on 05/02/2024 at 07:35, 6 months 21 days ago

Theranexus dévoile son document d'enregistrement universel pour 2023

2023 Biopharmaceutique Document D'Enregistrement Universel Theranexus Maladies Neurologiques Rares

Published on 11/22/2024 at 23:55, 10 hours 56 minutes ago

Boron One Announces Early Warrant Exercise Incentive Program
Published on 11/22/2024 at 23:30, 11 hours 21 minutes ago

Electric Royalties Enters Into Definitive Agreement to Acquire 0.75% Gross Revenue Royalty on Producing Punitaqui Copper Mine in Chile
Published on 11/22/2024 at 23:05, 11 hours 46 minutes ago

Kidoz Inc. Announces Results of 2024 AGM
Published on 11/22/2024 at 23:05, 11 hours 46 minutes ago

Nexa Resources Announces Closing Transaction of Pukaqaqa Project Sale to Olympic
Published on 11/22/2024 at 22:30, 12 hours 21 minutes ago

Delaforce Energy Corp. Announces Acquisition of Bouchard Well Service Ltd.

View all ACCESSWIRE

Published on 11/22/2024 at 18:14, 16 hours 37 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/22/2024 at 18:00, 16 hours 51 minutes ago

Holding(s) in Company
Published on 11/22/2024 at 17:53, 16 hours 58 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/22/2024 at 16:55, 17 hours 56 minutes ago

EQS-Adhoc: Comment on withdrawn non-binding offer
Published on 11/22/2024 at 16:00, 18 hours 51 minutes ago

Proposed cancellation of admission to trading

View all EQS

Published on 11/22/2024 at 17:45, 17 hours 6 minutes ago

IMMERSION : RFA 2023/2024
Published on 11/22/2024 at 16:15, 18 hours 36 minutes ago

NRJ GROUP - Le Conseil d'Etat rejette le recours de NRJ 12 et NRJ GROUP
Published on 11/22/2024 at 14:35, 20 hours 16 minutes ago

Communiqué de presse Thales
Published on 11/22/2024 at 14:35, 20 hours 16 minutes ago

Thales Press release
Published on 11/21/2024 at 06:58, 2 days 3 hours ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio

View all LES ECHOS COMFI WIRE

News